title: Tandem high-dose chemotherapy and autologous stem cell transplantation for anaplastic ependymoma in children younger than 3 years of age.
abstract: The present study evaluates the feasibility and effectiveness of tandem high-dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT) in very young children with anaplastic ependymoma. We aimed both to improve survival and to avoid unacceptable late adverse effects of radiation therapy (RT) by avoiding or deferring RT until 3 years of age. Five consecutive patients younger than 3 years of age with anaplastic ependymoma were enrolled from April 2006 to November 2008. Tandem HDCT/autoSCT was given following six cycles of induction chemotherapy. RT was either not given or deferred until 3 years of age if the patient was in complete response after tandem HDCT/autoSCT. Median age at diagnosis was 16 (range 12-28) months. Four patients had significant residual tumor (>1.5 cm(2)) after initial surgery, and three had leptomeningeal seeding. Toxicities during induction chemotherapy and tandem HDCT/autoSCT were manageable. No tumor progressed during induction chemotherapy and tandem HDCT/autoSCT, and RT was thus avoided or deferred until 3 years of age in all patients. All patients are alive at median follow-up of 45 (range 31-62) months from diagnosis, although tumor progressed in one patient. No significant endocrine dysfunction occurred except for hypothyroidism in one patient. Cognitive function was also acceptable in all patients but one who had significant neurologic injury during surgery. Our results indicate that treatment with tandem HDCT/autoSCT is feasible in very young children with anaplastic ependymoma and may improve the survival of patients with acceptable long-term toxicity.
authors.affiliation: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
authors.forename: Ki Woong
authors.initials: KW
authors.lastname: Sung
authors.forename: Do Hoon
authors.initials: DH
authors.lastname: Lim
authors.forename: Soo Hyun
authors.initials: SH
authors.lastname: Lee
authors.forename: Keon Hee
authors.initials: KH
authors.lastname: Yoo
authors.forename: Hong Hoe
authors.initials: HH
authors.lastname: Koo
authors.forename: Ji Hye
authors.initials: JH
authors.lastname: Kim
authors.forename: Yeon-Lim
authors.initials: YL
authors.lastname: Suh
authors.forename: Yoo Sook
authors.initials: YS
authors.lastname: Joung
authors.forename: Hyung Jin
authors.initials: HJ
authors.lastname: Shin
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery*; D002675:Child, Preschool; D018572:Disease-Free Survival; D004806:Ependymoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D011810:Quinoxalines / Q000627:therapeutic use; D011881:Radiotherapy, Computer-Assisted; D012189:Retrospective Studies; D033581:Stem Cell Transplantation / Q000379:methods*; D014182:Transplantation, Autologous / Q000379:methods; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011810:Quinoxalines; C017738:TANDEM (quinoxaline)
references.citation: J Negat Results Biomed. 2011 May 31;10:7
references.pmid: 21627842
references.citation: J Clin Oncol. 1999 Nov;17(11):3476-86
references.pmid: 10550145
references.citation: J Neurosurg. 2000 Oct;93(4):605-13
references.pmid: 11014538
references.citation: Mod Pathol. 2008 Feb;21(2):165-77
references.pmid: 18084249
references.citation: Med Pediatr Oncol. 1990;18(4):304-10
references.pmid: 2355890
references.citation: Pediatr Blood Cancer. 2007 Apr;48(4):408-15
references.pmid: 17066462
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Neurosurgery. 1997 Apr;40(4):856-60; discussion 860
references.pmid: 9092863
references.citation: Lancet Oncol. 2007 Aug;8(8):696-705
references.pmid: 17644039
references.citation: Pediatr Blood Cancer. 2008 Feb;50(2):231-5
references.pmid: 17610266
references.citation: J Clin Oncol. 2005 Oct 20;23(30):7621-31
references.pmid: 16234523
references.citation: J Neurosurg. 1998 Apr;88(4):695-703
references.pmid: 9525716
references.citation: Bone Marrow Transplant. 2008 Jan;41(2):167-72
references.pmid: 18176620
references.citation: J Clin Oncol. 2001 Mar 1;19(5):1288-96
references.pmid: 11230470
references.citation: Pediatr Neurosurg. 1998 Jul;29(1):40-5
references.pmid: 9755311
references.citation: J Clin Oncol. 1998 Jan;16(1):210-21
references.pmid: 9440745
references.citation: Crit Rev Oncol Hematol. 2007 Jul;63(1):81-9
references.pmid: 17482475
references.citation: J Clin Oncol. 2009 Mar 1;27(7):1007-13
references.pmid: 19171716
references.citation: Pediatr Blood Cancer. 2012 Mar;58(3):380-3
references.pmid: 21370439
references.citation: Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):52-7
references.pmid: 12007941
references.citation: Lancet Oncol. 2004 Jul;5(7):399-408
references.pmid: 15231246
references.citation: Radiother Oncol. 2005 Dec;77(3):278-85
references.pmid: 16300848
references.citation: Lancet Oncol. 2005 Sep;6(9):649-58
references.pmid: 16129365
references.citation: Pediatr Neurosurg. 1998 Mar;28(3):135-42
references.pmid: 9705591
references.citation: Pediatr Blood Cancer. 2007 Jul;49(1):34-40
references.pmid: 16874765
references.citation: Pediatr Blood Cancer. 2008 Feb;50(2):312-8
references.pmid: 17668858
references.citation: Lancet Oncol. 2009 Mar;10(3):258-66
references.pmid: 19274783
references.citation: Neurologist. 2004 Nov;10(6):293-310
references.pmid: 15518596
references.citation: Cancer. 1997 Jul 15;80(2):341-7
references.pmid: 9217048
references.citation: J Neurosurg. 2002 Oct;97(4):827-35
references.pmid: 12405370